General Information of Drug Transporter (DT)
DT ID	DTD0002 Transporter Info
Gene Name	ABCC2
Protein Name	Multidrug resistance-associated protein 2
Gene ID	1244
UniProt ID	Q92887
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs113646094
Site of GPD	chr10:99804255 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	G=0.0032/16 (Global)
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Pravastatin	Drug Info	Healthy Individuals	Correlated with the increased drug clearance in healthy individuals (compare with genotype CC)		[ 1]
Pravastatin	Drug Info	Hypercholesterolemia	Correlated with the increased expression of ABCC2 mRnA in human liver samples (compare with genotype CC)		[ 1]
Pravastatin	N.A.	Peripheral Nervous System Diseases	Genotype CG is associated with increased clearance of pravastatin in healthy individuals as compared to genotype CC.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Pravastatin	N.A.	Breast Neoplasms	Patients with the CC genotype may have decreased clearance of pravastatin as compared to patients with the CG genotype. Other genetic and clinical factors may also influence clearance of pravastatin.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Pravastatin	N.A.	Breast Neoplasms	No patients with the GG genotype were available for analysis, but patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.		[ 1]
Genetic Polymorphism	rs12762549
Site of GPD	chr10:99861014 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	G=0.4806/2407 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Docetaxel	Drug Info	Neoplasm	Irrelevant to the neutropenia in patients (compare with genotypes CG + GG)		[ 2]
Docetaxel	N.A.	Neutropenia	Genotype CC is not associated with Neutropenia when treated with docetaxel in people with Neoplasms as compared to genotypes CG + GG.		[ 2]
Docetaxel	N.A.	HIV Infectious Disease	Genotype CC is not associated with Neutropenia when treated with docetaxel in people with Neoplasms as compared to genotypes CG + GG.		[ 2]
Genotypes CG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	Drug Info	Breast Neoplasm	Correlated with the decreased drug clearance (compare with genotype CC)		[ 2]
Docetaxel	N.A.	Transplant Rejection	Genotypes CG + GG are associated with decreased clearance of docetaxel as compared to genotype CC.		[ 2]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Leukopenia	Allele G is associated with increased risk of Leukopenia when treated with docetaxel.		[ 3]
Docetaxel	N.A.	HIV Infectious Disease	Allele G is associated with increased risk of Leukopenia when treated with docetaxel.		[ 3]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Docetaxel	N.A.	HIV Infectious Disease	Patients with the CG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Docetaxel	N.A.	HIV Infectious Disease	Patients with the GG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.		[ 2]
Genetic Polymorphism	rs17222723
Site of GPD	chr10:99836239 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Minor Allele Frequency	A=0.0373/187 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:         18 Drugs in Total
Tenofovir	Drug Info	HIV Infection	Correlated with the decreased renal proximal tubulopathy risk in patients (compare with Allele T); Irrelevant to the increased kidney tubular dysfunction risk in patients (compare with Allele T)		[ 4], [ 5]
Doxorubicin	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased cardiotoxicity risk in patients (compare with Allele T)		[ 6]
Methotrexate	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with clearance of methotrexate in people with Lymphoma.		[ 7]
Pravastatin	N.A.	Mucositis	Allele A is not associated with pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to allele T.		[ 8]
Doxorubicin	N.A.	Mucositis	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele T.		[ 6]
Antineoplastic Agents	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 9]
Corticosteroids	N.A.	Drug Toxicity	Allele A is not associated with risk of Drug Toxicity when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 9]
Cyclophosphamide	N.A.	Peripheral Nervous System Diseases	Allele A is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele T.		[ 10]
Epirubicin	N.A.	Peripheral Nervous System Diseases	Allele A is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele T.		[ 10]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele A is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele T.		[ 10]
Tenofovir	N.A.	Nephrotoxicity	Allele A is associated with decreased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele T.		[ 4]
Tenofovir	N.A.	Nephrotoxicity	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele T.		[ 5]
Methotrexate	N.A.	Neurotoxicity Syndromes	Allele A is associated with increased likelihood of Neurotoxicity Syndromes when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to allele T.		[ 11]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele T.		[ 5]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is associated with decreased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele T.		[ 4]
Doxorubicin	N.A.	Cardiac Rhythm Disease	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele T.		[ 6]
Doxorubicin	N.A.	Drug Toxicity	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele T.		[ 6]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele T.		[ 6]
Genotypes AT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Leukopenia	Genotypes AT + TT are associated with increased risk of Leukopenia when treated with methotrexate in people with Osteosarcoma as compared to genotype AA.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Genotypes AT + TT are associated with increased risk of Leukopenia when treated with methotrexate in people with Osteosarcoma as compared to genotype AA.		[ 12]
Genotypes AA + AT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclosporine	N.A.	Transplant Rejection	Genotypes AA + AT are not associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.		[ 13]
Mycophenolate Mofetil	N.A.	Transplant Rejection	Genotypes AA + AT are not associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.		[ 13]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Methotrexate	N.A.	Leukopenia	Patients with osteosarcoma and the rs17222723 AA genotype may have a decreased risk of developing leukopenia when treated with methotrexate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs17222723 AA genotype may have a decreased risk of developing leukopenia when treated with methotrexate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.		[ 12]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.		[ 5]
Doxorubicin	N.A.	Cardiac Rhythm Disease	Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Drug Toxicity	Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Genotype AT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Methotrexate	N.A.	Leukopenia	Patients with osteosarcoma and the rs17222723 AT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs17222723 AT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.		[ 12]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.		[ 5]
Doxorubicin	N.A.	Cardiac Rhythm Disease	Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Drug Toxicity	Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Methotrexate	N.A.	Leukopenia	Patients with osteosarcoma and the rs17222723 TT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs17222723 TT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.		[ 12]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV who are treated with tenofovir may have an increased risk of renal proximal tubulopathy as compared to patients with the AT and AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.		[ 5]
Doxorubicin	N.A.	Cardiac Rhythm Disease	Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Drug Toxicity	Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.		[ 6]
Genetic Polymorphism	rs2273697
Site of GPD	chr10:99804058 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.1865/934 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:         58 Drugs in Total
Mycophenolic acid	Drug Info	Kidney Transplantation	Correlated with the decreased drug exposure in patients (compare with allele G)		[ 14]
Tenofovir	Drug Info	HIV Infection	Correlated with the increased renal proximal tubulopathy risk in patients (compare with allele G); Irrelevant to the increased fanconi syndrome risk in patients (compare with Allele G); Irrelevant to the increased kidney tubular dysfunction risk in patients (compare with Allele G); Irrelevant to the likelihood of kidney diseases in patients (compare with Allele G)		[ 4], [ 5], [ 15], [ 16]
Methotrexate	Drug Info	Rheumatoid Arthritis	Irrelevant to the drug discontinuation in patients (compare with allele G)		[ 19]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the number of seizures per year in patients (compare with Allele G)		[ 20]
Oxcarbazepine	Drug Info	Epilepsy	Irrelevant to the number of seizures per year in patients (compare with Allele G)		[ 20]
Pitavastatin	N.A.	Drug Toxicity	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.		[ 21]
Olanzapine	N.A.	Toxic Liver Disease	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.		[ 22]
Mycophenolate Mofetil	N.A.	Neurotoxicity Syndromes	Allele A is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 23]
Carbamazepine	N.A.	Neutropenia	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.		[ 24]
Methotrexate	N.A.	Kidney Tubular Necrosis, Acute	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 19]
Cisplatin	N.A.	Kidney Tubular Necrosis, Acute	Allele A is not associated with nephrotoxicity (geometirc changes in serum creatinine level) when treated with cisplatin in people with Neoplasms as compared to allele G.		[ 25]
Methotrexate	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with clearance of methotrexate in people with Lymphoma.		[ 7]
Pravastatin	N.A.	Mucositis	Allele A is not associated with pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to allele G.		[ 8]
Methotrexate	N.A.	Mucositis	Allele A is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 28]
Talinolol	N.A.	Mucositis	Allele A is not associated with clearance of talinolol in healthy individuals as compared to allele G.		[ 29]
Lacosamide	N.A.	Mucositis	Allele A is associated with increased resistance to lacosamide in children with Epilepsy as compared to allele G.		[ 30]
Methotrexate	N.A.	Bone Marrow Disorder	Allele A is associated with increased risk of Bone Marrow Diseases when treated with methotrexate in children with Osteosarcoma as compared to allele G.		[ 31]
Tenofovir	N.A.	Fanconi Renotubular Syndrome	Allele A is not associated with increased risk of Fanconi Syndrome when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 15]
Mycophenolic Acid	N.A.	Decreased Glomerular Filtration Rate	Allele A is associated with decreased exposure to mycophenolic acid as compared to allele G.		[ 14]
Tenofovir	N.A.	Kidney Disorder	Allele A is not associated with likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 16]
Methotrexate	N.A.	Kidney Disorder	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 32]
Oxcarbazepine	N.A.	Kidney Disorder	Allele A is associated with increased dose of oxcarbazepine in people with Epilepsy as compared to allele G.		[ 33]
Antiepileptics	N.A.	Kidney Disorder	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 34]
Methotrexate	N.A.	Drug Toxicity	Allele A is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele G.		[ 35]
Methotrexate	N.A.	Nausea	Allele A is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele G.		[ 35]
Antiepileptics	N.A.	Nausea	Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G.		[ 36]
Tacrolimus	N.A.	Nausea	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.		[ 37]
Platinum Compounds	N.A.	Drug Toxicity	Allele A is not associated with severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.		[ 38]
Oxcarbazepine	N.A.	Drug Toxicity	Allele A is not associated with response to oxcarbazepine in people with Epilepsy as compared to allele G.		[ 39]
Methotrexate	N.A.	Transplant Rejection	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.		[ 40]
Antiepileptics	N.A.	Toxic Liver Disease	Allele A is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele G.		[ 20]
Lamotrigine	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to lamotrigine in people with Epilepsy as compared to allele G.		[ 41]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Allele A is not associated with severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to allele G.		[ 42]
Tenofovir	N.A.	Nephrotoxicity	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 4]
Tenofovir	N.A.	Nephrotoxicity	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 5]
Talinolol	N.A.	Progression-free Survival	Allele A is associated with increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol when exposed to talinolol as compared to allele G.		[ 43]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 34]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 34]
Oxcarbazepine	N.A.	Epilepsy	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 34]
Antiepileptics	N.A.	Epilepsy	Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G.		[ 36]
Carbamazepine	N.A.	Epilepsy	Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G.		[ 36]
Oxcarbazepine	N.A.	Epilepsy	Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G.		[ 36]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.		[ 24]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.		[ 24]
Oxcarbazepine	N.A.	Epilepsy	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.		[ 24]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele G.		[ 20]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele G.		[ 20]
Oxcarbazepine	N.A.	Epilepsy	Allele A is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele G.		[ 20]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is not associated with likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 16]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 5]
Tenofovir	N.A.	Kidney Disorder	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 5]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 4]
Tenofovir	N.A.	Kidney Disorder	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 4]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is not associated with increased risk of Fanconi Syndrome when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 15]
Tenofovir	N.A.	Kidney Disorder	Allele A is not associated with increased risk of Fanconi Syndrome when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 15]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele A is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele G.		[ 35]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 19]
Antiepileptics	N.A.	Epilepsy	Correlated with the increased probability of drug response in patients (compare with allele G); Irrelevant to the drug resistance in patients (compare with Allele G); Irrelevant to the drug resistance in patients (compare with Allele G); Irrelevant to the number of seizures per year in patients (compare with Allele G)		[ 20], [ 34], [ 36], [ 44]
Allele G	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Mycophenolic acid	Drug Info	Kidney Transplantation	Irrelevant to the drug metabolism in patients (compare with allele A)		[ 41]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the increased drug resistance in patients (compare with allele A)		[ 42]
Oxcarbazepine	Drug Info	Epilepsy	Irrelevant to the increased drug resistance in patients (compare with allele A)		[ 42]
10-monohydroxy Oxcarbazepine	N.A.	Cardiotoxicity	Allele G is associated with increased clearance of 10-monohydroxy oxcarbazepine in children with Epilepsy as compared to allele A.		[ 43]
Antiepileptics	N.A.	Neutropenia	Allele G is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 42]
Tamoxifen	N.A.	Drug Toxicity	Allele G is not associated with increased or decreased recurrence-free survival time when treated with tamoxifen as compared to allele A.		[ 44]
Mycophenolic Acid	N.A.	Peripheral Nervous System Diseases	Allele G is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele A.		[ 41]
Antiepileptics	N.A.	Epilepsy	Allele G is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 42]
Carbamazepine	N.A.	Epilepsy	Allele G is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 42]
Oxcarbazepine	N.A.	Epilepsy	Allele G is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 42]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the increased drug resistance in patients (compare with allele A)		[ 42]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:         26 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased likelihood of drug toxicity in patients (compare with genotypes AG + GG)		[ 45]
Rasagiline	N.A.	Drug Toxicity	Genotype AA is associated with decreased clearance of rasagiline in healthy individuals as compared to genotypes AG + GG.		[ 46]
Clopidogrel	N.A.	Neurotoxicity Syndromes	Genotype AA is not associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.		[ 47]
Methotrexate	N.A.	Leukopenia	Genotype AA is not associated with basal urinary coproporphyrin I/ (I+III) ratio when treated with methotrexate in people with Lymphoma as compared to genotype GG.		[ 48]
Ezetimibe	N.A.	Neutropenia	Genotype AA is associated with increased dose-adjusted trough concentrations of ezetimibe in healthy individuals as compared to genotypes AG + GG.		[ 49]
N-desmethyltramadol	N.A.	Drug Toxicity	Genotype AA is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotypes AG + GG.		[ 50]
O-desmethyltramadol	N.A.	Drug Toxicity	Genotype AA is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotypes AG + GG.		[ 50]
Methotrexate	N.A.	Drug Toxicity	Genotype AA is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.		[ 45]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	No patients with the AA genotype were available for analysis. However, patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.		[ 51]
Antiepileptics	N.A.	Epilepsy	Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Carbamazepine	N.A.	Epilepsy	Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Oxcarbazepine	N.A.	Epilepsy	Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with AA genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		[ 53]
Doxorubicin	N.A.	Breast Neoplasms	Patients with AA genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		[ 53]
Fluorouracil	N.A.	Breast Neoplasms	Patients with AA genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		[ 53]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.		[ 54]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AA genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.		[ 55]
Ceftriaxone	N.A.	Central Nervous System Infectious Disorder	Patients with central nervous system infections and the AA genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.		[ 56]
Carbamazepine	N.A.	Epilepsy	Patients with the AA genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.		[ 57]
Cisplatin	N.A.	Mesothelioma	Patients with mesothelioma and the AA genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.		[ 58]
Pemetrexed	N.A.	Mesothelioma	Patients with mesothelioma and the AA genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.		[ 58]
Talinolol	N.A.	Mesothelioma	People with the rs2273697 AA genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.		[ 39]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the AA genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 60]
Tenofovir	N.A.	Kidney Disorder	Patients with the AA genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 60]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype AA is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.		[ 45]
Methotrexate	N.A.	Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs2273697 AA genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 31]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:         33 Drugs in Total
Mycophenolic acid	Drug Info	Lung Transplantation	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 59]
Carbamazepine	Drug Info	Epilepsy	Correlated with the relationship with drug resistance in patients (compare with genotype GG)		[ 60]
Oxcarbazepine	Drug Info	Epilepsy	Correlated with the relationship with drug resistance in patients (compare with genotype GG)		[ 60]
Mycophenolate Mofetil	N.A.	Febrile Neutropenia	Genotype AG is associated with increased area under the concentration versus time curve (AUC6-12) level of the acyl glucuronide of mycophenolic acid when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.		[ 61]
Carbamazepine	N.A.	Kidney Tubular Necrosis, Acute	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.		[ 60]
Oxcarbazepine	N.A.	Kidney Tubular Necrosis, Acute	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.		[ 60]
Deferasirox	N.A.	Mucositis	Genotype AG is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype GG.		[ 62]
Deferasirox	N.A.	Kidney Disorder	Genotype AG is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG.		[ 51]
Atorvastatin	N.A.	Kidney Disorder	Genotype AG is associated with decreased response to atorvastatin in healthy individuals as compared to genotype GG.		[ 64]
Lamotrigine	N.A.	Peripheral Nervous System Diseases	Genotype AG is not associated with concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.		[ 37]
Mycophenolic Acid	N.A.	Peripheral Nervous System Diseases	Genotype AG is associated with increased concentrations of mycophenolic acid in people with lung transplantation as compared to genotype GG.		[ 59]
Deferasirox	N.A.	Drug Toxicity	Genotype AG is associated with increased severity of Drug Toxicity when treated with deferasirox in children with Beta-thalassemia and related diseases as compared to genotype GG.		[ 66]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Genotype AG is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG.		[ 51]
Antiepileptics	N.A.	Epilepsy	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.		[ 60]
Carbamazepine	N.A.	Epilepsy	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.		[ 60]
Oxcarbazepine	N.A.	Epilepsy	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.		[ 60]
Antiepileptics	N.A.	Epilepsy	Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Carbamazepine	N.A.	Epilepsy	Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Oxcarbazepine	N.A.	Epilepsy	Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		[ 52]
Doxorubicin	N.A.	Breast Neoplasms	Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		[ 52]
Fluorouracil	N.A.	Breast Neoplasms	Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.		[ 52]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.		[ 53]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AG genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.		[ 54]
Ceftriaxone	N.A.	Central Nervous System Infectious Disorder	Patients with central nervous system infections and the AG genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.		[ 55]
Carbamazepine	N.A.	Epilepsy	Patients with the AG genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.		[ 56]
Cisplatin	N.A.	Mesothelioma	Patients with mesothelioma and the AG genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.		[ 57]
Pemetrexed	N.A.	Mesothelioma	Patients with mesothelioma and the AG genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.		[ 57]
Talinolol	N.A.	Mesothelioma	People with the rs2273697 AG genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.		[ 39]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 58]
Tenofovir	N.A.	Kidney Disorder	Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 58]
Methotrexate	N.A.	Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs2273697 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 31]
Exjade	N.A.	Beta-Thalassemia	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 51]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:         33 Drugs in Total
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotypes AA + AG)		[ 52]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotypes AA + AG)		[ 52]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotypes AA + AG)		[ 52]
Mycophenolic acid	Drug Info	Kidney Transplantation	Irrelevant to the any pharmacokinetic parameters measured in the study in patients (compare with genotype AA)		[ 66]
Anthracyclines And Related Substances	N.A.	Febrile Neutropenia	Genotype GG is associated with increased likelihood of febrile neutropenia when treated with anthracyclines and related substances in people with Soft Tissue Neoplasms and Sarcoma as compared to genotypes AA + AG.		[ 67]
Folfiri	N.A.	Diarrhea	Genotype GG is associated with decreased severity of Diarrhea when treated with FOLFIRI in people with Pancreatic Neoplasms as compared to genotypes AA + AG.		[ 68]
Mycophenolic Acid	N.A.	Leukopenia	Genotype GG is not associated with any pharmacokinetic parameters measured in the study when exposed to mycophenolic acid as compared to genotype AA.		[ 66]
Lacosamide	N.A.	Mucositis	Genotype GG is associated with increased concentrations of lacosamide in children with Epilepsy as compared to genotypes AA + AG.		[ 26]
Irinotecan	N.A.	Diarrhea	Genotype GG is not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 70]
Irinotecan	N.A.	Neutropenia	Genotype GG is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 70]
Oxcarbazepine	N.A.	Drug Toxicity	Genotype GG is not associated with concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes AA + AG.		[ 35]
Ceftriaxone	N.A.	Transplant Rejection	Genotype GG is associated with decreased concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes AA + AG.		[ 55]
Cyclophosphamide	N.A.	Anemia	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 52]
Doxorubicin	N.A.	Anemia	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 52]
Fluorouracil	N.A.	Anemia	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 52]
Imatinib	N.A.	Progression-free Survival	Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.		[ 53]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Patients with the GG genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.		[ 51]
Antiepileptics	N.A.	Epilepsy	Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Carbamazepine	N.A.	Epilepsy	Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Oxcarbazepine	N.A.	Epilepsy	Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 30]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 52]
Doxorubicin	N.A.	Breast Neoplasms	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 52]
Fluorouracil	N.A.	Breast Neoplasms	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 52]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.		[ 53]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the GG genotype and colorectal cancer may have decreased metabolism of irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.		[ 54]
Ceftriaxone	N.A.	Central Nervous System Infectious Disorder	Genotype GG is associated with decreased concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes AA + AG.		[ 55]
Carbamazepine	N.A.	Epilepsy	Patients with the GG genotype and epilepsy who are treated with carbamazepine may have a reduced, but not absent, risk of neurological adverse drug reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.		[ 56]
Cisplatin	N.A.	Mesothelioma	Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.		[ 57]
Pemetrexed	N.A.	Mesothelioma	Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.		[ 57]
Talinolol	N.A.	Mesothelioma	People with the rs2273697 GG genotype may have decreased clearance of talinolol as compared to people with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.		[ 39]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 58]
Tenofovir	N.A.	Kidney Disorder	Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 58]
Methotrexate	N.A.	Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs2273697 GG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 31]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:         33 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased drug metabolism in patients (compare with genotype GG)		[ 54]
Carbamazepine	Drug Info	Epilepsy	Correlated with the increased neurological ADR risk in patients (compare with genotype GG); Irrelevant to the drug response in patients (compare with genotype GG)		[ 56], [ 70]
Cisplatin	Drug Info	Mesothelioma	Correlated with the increased overall survival and progression-free survival in patients (compare with genotype GG)		[ 57]
Pemetrexed	Drug Info	Mesothelioma	Correlated with the increased overall survival and progression-free survival in patients (compare with genotype GG)		[ 57]
Tenofovir	Drug Info	HIV Infection	Irrelevant to the glomerular disease in patients (compare with genotype GG)		[ 58]
Cisplatin	N.A.	Overall Survival	Genotypes AA + AG are associated with increased overall survival and progression-free survival when treated with cisplatin and pemetrexed in people with Mesothelioma as compared to genotype GG.		[ 57]
Cisplatin	N.A.	Progression-free Survival	Genotypes AA + AG are associated with increased overall survival and progression-free survival when treated with cisplatin and pemetrexed in people with Mesothelioma as compared to genotype GG.		[ 57]
Pemetrexed	N.A.	Overall Survival	Genotypes AA + AG are associated with increased overall survival and progression-free survival when treated with cisplatin and pemetrexed in people with Mesothelioma as compared to genotype GG.		[ 57]
Pemetrexed	N.A.	Progression-free Survival	Genotypes AA + AG are associated with increased overall survival and progression-free survival when treated with cisplatin and pemetrexed in people with Mesothelioma as compared to genotype GG.		[ 57]
Antiepileptics	N.A.	Neurotoxicity Syndromes	Genotypes AA + AG are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 74]
Irinotecan	N.A.	Neurotoxicity Syndromes	Genotypes AA + AG are associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype GG.		[ 54]
Carbamazepine	N.A.	Neurotoxicity Syndromes	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.		[ 75]
Tenofovir	N.A.	Kidney Disorder	Genotypes AA + AG are not associated with Kidney Disorder when exposed to tenofovir in people with HIV infectious disease as compared to genotype GG.		[ 58]
Carbamazepine	N.A.	Leukopenia	Genotypes AA + AG is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype GG.		[ 70]
Cisplatin	N.A.	Peripheral Nervous System Diseases	Genotypes AA + AG is associated with decreased clinical benefit to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 76]
Doxorubicin	N.A.	Peripheral Nervous System Diseases	Genotypes AA + AG is associated with decreased clinical benefit to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 76]
Methotrexate	N.A.	Peripheral Nervous System Diseases	Genotypes AA + AG is associated with decreased clinical benefit to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype GG.		[ 76]
Tenofovir	N.A.	Bone Marrow Disorder	Genotypes AA + AG is not associated with concentrations of tenofovir in people with HIV Infections as compared to genotype GG.		[ 77]
Methotrexate	N.A.	Toxic Liver Disease	Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 78]
Tenofovir	N.A.	Toxic Liver Disease	Genotypes AA + AG is not associated with increased discontinuation of tenofovir in people with HIV Infections as compared to genotype GG.		[ 79]
Carbamazepine	N.A.	Progression-free Survival	Genotypes AA + AG are associated with increased risk of neurological ADR when treated with carbamazepine in people with Epilepsy as compared to genotype GG.		[ 56]
Antiepileptics	N.A.	Epilepsy	Genotypes AA + AG are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 18]
Carbamazepine	N.A.	Epilepsy	Genotypes AA + AG are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 18]
Oxcarbazepine	N.A.	Epilepsy	Genotypes AA + AG are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 18]
Antiepileptics	N.A.	Epilepsy	Genotypes AA + AG is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype GG.		[ 70]
Carbamazepine	N.A.	Epilepsy	Genotypes AA + AG is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype GG.		[ 70]
Oxcarbazepine	N.A.	Epilepsy	Genotypes AA + AG is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype GG.		[ 70]
Irinotecan	N.A.	Colorectal Neoplasms	Genotypes AA + AG are associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype GG.		[ 54]
Carbamazepine	N.A.	Epilepsy	Genotypes AA + AG are associated with increased risk of neurological ADR when treated with carbamazepine in people with Epilepsy as compared to genotype GG.		[ 56]
Cisplatin	N.A.	Mesothelioma	Genotypes AA + AG are associated with increased overall survival and progression-free survival when treated with cisplatin and pemetrexed in people with Mesothelioma as compared to genotype GG.		[ 57]
Pemetrexed	N.A.	Mesothelioma	Genotypes AA + AG are associated with increased overall survival and progression-free survival when treated with cisplatin and pemetrexed in people with Mesothelioma as compared to genotype GG.		[ 57]
Tenofovir	N.A.	HIV Infectious Disease	Genotypes AA + AG are not associated with Kidney Disorder when exposed to tenofovir in people with HIV infectious disease as compared to genotype GG.		[ 58]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the increased drug resistance in patients (compare with genotype GG)		[ 18]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Recurrence Free Survival	Genotypes AG + GG is associated with increased Recurrence free survival when treated with anthracyclines and related substances in people with Soft Tissue Neoplasms and Sarcoma as compared to genotype AA.		[ 66]
Genetic Polymorphism	rs3740065
Site of GPD	chr10:99845936 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.2011/1007 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:         17 Drugs in Total
Tamoxifen	Drug Info	Breast Neoplasm	Correlated with the increased recurrence of breast cancer risk in patients (compare with genotype GG)		[ 44]
Cyclosporine	N.A.	Graft Vs Host Disease	Genotype AA is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype AG.		[ 77]
Methotrexate	N.A.	Graft Vs Host Disease	Genotype AA is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype AG.		[ 77]
Tamoxifen	N.A.	Drug Toxicity	Genotype AA is associated with increased risk of recurrence of breast cancer when treated with tamoxifen in women with Breast Neoplasms as compared to genotype GG.		[ 44]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs3740065 AA genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs3740065 AA genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs3740065 AA genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Lymphoma	Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Mucositis	Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Non-small Cell Lung Carcinoma	Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Tamoxifen	N.A.	Breast Neoplasms	Genotype AA is associated with increased risk of recurrence of breast cancer when treated with tamoxifen in women with Breast Neoplasms as compared to genotype GG.		[ 44]
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Patients with tuberculosis and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.		[ 80]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Patients with tuberculosis and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.		[ 80]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:         16 Drugs in Total
Tamoxifen	Drug Info	Breast Neoplasm	Irrelevant to the disease recurrence risk in patients (compare with genotype AA)		[ 78]
Tamoxifen	N.A.	Drug Toxicity	Genotype AG is not associated with risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotype AA.		[ 78]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs3740065 AG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs3740065 AG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs3740065 AG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Lymphoma	Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Mucositis	Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Non-small Cell Lung Carcinoma	Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Tamoxifen	N.A.	Breast Neoplasms	Genotype AG is not associated with risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotype AA.		[ 78]
Tamoxifen	N.A.	Breast Neoplasms	No significant association with breast cancer disease recurrence has been seen for patients with the AG genotype as compared to the AA genotype.		[ 44]
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Patients with tuberculosis and the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.		[ 77]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Patients with tuberculosis and the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.		[ 77]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Methotrexate	Drug Info	Acute B-Cell Leukemia	Correlated with the increased drug plasma level in patients (compare with genotype AA); Correlated with the increased toxicity risk in patients (compare with genotype AA)		[ 79]
Methotrexate	N.A.	Toxic Liver Disease	Genotypes AG + GG are associated with increased plasma level when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 79]
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Genotypes AG + GG are associated with decreased risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype AA.		[ 77]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AG + GG are associated with increased plasma level when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 79]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes AG + GG are associated with increased plasma level when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 79]
Methotrexate	N.A.	Osteosarcoma	Genotypes AG + GG are associated with increased plasma level when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 79]
Methotrexate	N.A.	Drug Toxicity	Genotypes AG + GG are associated with increased risk of toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 79]
Methotrexate	N.A.	Lymphoma	Genotypes AG + GG are associated with increased risk of toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 79]
Methotrexate	N.A.	Mucositis	Genotypes AG + GG are associated with increased risk of toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 79]
Methotrexate	N.A.	Non-small Cell Lung Carcinoma	Genotypes AG + GG are associated with increased risk of toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 79]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Genotypes AG + GG are associated with decreased risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype AA.		[ 77]
Allele G	Click to Show/Hide the Full List of Affected Drugs:         20 Drugs in Total
Tamoxifen	N.A.	Neurotoxicity Syndromes	Allele G is associated with increased discontinuation of tamoxifen in women with Breast Neoplasms.		[ 80]
Methotrexate	N.A.	Toxic Liver Disease	Allele G is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 81]
Methotrexate	N.A.	Mucositis	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 24]
Methotrexate	N.A.	Kidney Disorder	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 28]
Methotrexate	N.A.	Transplant Rejection	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 36]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 28]
Methotrexate	N.A.	Burkitt Lymphoma	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 28]
Methotrexate	N.A.	Osteosarcoma	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 28]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 81]
Methotrexate	N.A.	Burkitt Lymphoma	Allele G is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 81]
Methotrexate	N.A.	Osteosarcoma	Allele G is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 81]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 36]
Methotrexate	N.A.	Burkitt Lymphoma	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 36]
Methotrexate	N.A.	Osteosarcoma	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 36]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 24]
Methotrexate	N.A.	Burkitt Lymphoma	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 24]
Methotrexate	N.A.	Drug Toxicity	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 24]
Methotrexate	N.A.	Lymphoma	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 24]
Methotrexate	N.A.	Non-small Cell Lung Carcinoma	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 24]
Methotrexate	N.A.	Osteosarcoma	Allele G is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 24]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs3740065 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs3740065 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs3740065 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 28]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Lymphoma	Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Mucositis	Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Non-small Cell Lung Carcinoma	Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.		[ 24]
Tamoxifen	N.A.	Breast Neoplasms	Patients with the GG genotype and breast cancer may have a decreased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also influence breast cancer recurrence.		[ 44]
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Patients with tuberculosis and the GG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.		[ 77]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Patients with tuberculosis and the GG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.		[ 77]
Genetic Polymorphism	rs3740066
Site of GPD	chr10:99844450 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	T=0.2881/1443 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Mycophenolic acid	Drug Info	Kidney Transplantation	Irrelevant to the drug metabolism in patients (compare with Allele T)		[ 41]
Platinum Compounds	N.A.	Drug Toxicity	Allele C is not associated with severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.		[ 34]
Antiepileptics	N.A.	Peripheral Nervous System Diseases	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 40]
Mycophenolic Acid	N.A.	Peripheral Nervous System Diseases	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.		[ 41]
Mycophenolic Acid	N.A.	Organ Transplantation	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.		[ 41]
Antiepileptics	N.A.	Epilepsy	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 40]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the drug resistance in patients (compare with Allele T)		[ 40]
Allele T	Click to Show/Hide the Full List of Affected Drugs:         18 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug trough concentration in patients (compare with allele C)		[ 33]
Pitavastatin	N.A.	Drug Toxicity	Allele T is not associated with exposure to pitavastatin in healthy individuals as compared to allele C.		[ 19]
Rosuvastatin	N.A.	Nausea	Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.		[ 84]
Mycophenolate Mofetil	N.A.	Neurotoxicity Syndromes	Allele T is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.		[ 21]
Azathioprine	N.A.	Neutropenia	Allele T is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele C.		[ 86]
Mycophenolic Acid	N.A.	Neutropenia	Allele T is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele C.		[ 86]
Cisplatin	N.A.	Kidney Tubular Necrosis, Acute	Allele T is not associated with clearance of unbound cisplatin when treated with cisplatin in people with Neoplasms as compared to allele C.		[ 23]
Methotrexate	N.A.	Kidney Tubular Necrosis, Acute	Allele T is not associated with clearance of methotrexate in people with Lymphoma.		[ 7]
Tenofovir	N.A.	Fanconi Renotubular Syndrome	Allele T is not associated with clearance of tenofovir in people with HIV Infections as compared to allele C.		[ 89]
Methotrexate	N.A.	Drug Toxicity	Allele T is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.		[ 31]
Methotrexate	N.A.	Nausea	Allele T is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.		[ 31]
Tacrolimus	N.A.	Nausea	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.		[ 33]
Antiepileptics	N.A.	Discontinuation	Allele T is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele C.		[ 18]
Tenofovir	N.A.	Peripheral Nervous System Diseases	Allele T is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele C.		[ 5]
Vincristine	N.A.	Neurotoxicity Syndromes	Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 93]
Tacrolimus	N.A.	Kidney Transplantation	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.		[ 33]
Antiepileptics	N.A.	Epilepsy	Allele T is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele C.		[ 18]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the number of seizures per year in patients (compare with allele C)		[ 18]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased diarrhea risk in patients (compare with Genotypes CT + TT); Irrelevant to the neutropenia in patients (compare with Genotypes CT + TT)		[ 68]
Mycophenolic acid	Drug Info	Organ Transplantation	Irrelevant to the any pharmacokinetic parameters measured in the study (compare with Genotype TT)		[ 65]
Irinotecan	N.A.	Diarrhea	Genotype CC is associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.		[ 68]
Mycophenolic Acid	N.A.	Leukopenia	Genotype CC is not associated with any pharmacokinetic parameters measured in the study when exposed to mycophenolic acid as compared to genotype TT.		[ 65]
Irinotecan	N.A.	Neutropenia	Genotype CC is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.		[ 68]
Carbamazepine	N.A.	Epilepsy	Patients with the CC genotype may have increased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype TT or CT. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.		[ 71]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Genotype CC is associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.		[ 68]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with CC genotype and breast cancer may have a decreased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		[ 52]
Doxorubicin	N.A.	Breast Neoplasms	Patients with CC genotype and breast cancer may have a decreased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		[ 52]
Fluorouracil	N.A.	Breast Neoplasms	Patients with CC genotype and breast cancer may have a decreased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		[ 52]
Mycophenolic Acid	N.A.	Organ Transplantation	Genotype CC is not associated with any pharmacokinetic parameters measured in the study when exposed to mycophenolic acid as compared to genotype TT.		[ 65]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the CC genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus, and require an increased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.		[ 33]
Antiepileptics	N.A.	Epilepsy	Patients with the CC genotype and Epilepsy who are treated with antiepileptics may have a decreased risk of drug resistance as compared to patients with the CT or TT genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 18]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Mycophenolic acid	Drug Info	Lung Transplantation	Correlated with the decreased drug concentrations in patients (compare with genotypes CC + tt)		[ 59]
Mycophenolic Acid	N.A.	Peripheral Nervous System Diseases	Genotype CT is associated with decreased concentrations of mycophenolic acid in people with lung transplantation as compared to genotypes CC + TT.		[ 59]
Carbamazepine	N.A.	Epilepsy	Patients with the CT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.		[ 71]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.		[ 68]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		[ 52]
Doxorubicin	N.A.	Breast Neoplasms	Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		[ 52]
Fluorouracil	N.A.	Breast Neoplasms	Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.		[ 52]
Mycophenolic Acid	N.A.	Organ Transplantation	Genotype CT is associated with decreased concentrations of mycophenolic acid in people with lung transplantation as compared to genotypes CC + TT.		[ 59]
Mycophenolic Acid	N.A.	Organ Transplantation	Patients with the CT genotype and organ transplantation may have decreased concentrations of mycophenolic acid compared to patients with CC and TT genotypes. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.		[ 65]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the CT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.		[ 33]
Antiepileptics	N.A.	Epilepsy	Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 18]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         29 Drugs in Total
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotypes CC + CT)		[ 52]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotypes CC + CT)		[ 52]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotypes CC + CT)		[ 52]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the drug resistance in patients (compare with genotype CC)		[ 60]
Oxcarbazepine	Drug Info	Epilepsy	Irrelevant to the drug resistance in patients (compare with genotype CC)		[ 60]
Anthracyclines And Related Substances	N.A.	Febrile Neutropenia	Genotype TT is associated with increased likelihood of febrile neutropenia when treated with anthracyclines and related substances in people with Soft Tissue Neoplasms and Sarcoma as compared to genotypes CC + CT.		[ 66]
Anthracyclines And Related Substances	N.A.	Overall Survival	Genotype TT is associated with decreased overall survival when treated with anthracyclines and related substances in people with Soft Tissue Neoplasms and Sarcoma as compared to genotypes CC + CT.		[ 66]
Tacrolimus	N.A.	Overall Survival	Genotype TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 89]
Fluorouracil	N.A.	Neurotoxicity Syndromes	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 90]
Leucovorin	N.A.	Neurotoxicity Syndromes	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 90]
Oxaliplatin	N.A.	Neurotoxicity Syndromes	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 90]
Clopidogrel	N.A.	Neurotoxicity Syndromes	Genotype TT is not associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes CC + CT.		[ 47]
Methotrexate	N.A.	Leukopenia	Genotype TT is not associated with basal urinary coproporphyrin I/ (I+III) ratio when treated with methotrexate in people with Lymphoma as compared to genotype CC.		[ 48]
Carbamazepine	N.A.	Kidney Tubular Necrosis, Acute	Genotype TT is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.		[ 60]
Oxcarbazepine	N.A.	Kidney Tubular Necrosis, Acute	Genotype TT is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.		[ 60]
Methotrexate	N.A.	Nausea	Genotype TT is associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotypes CC + CT.		[ 27]
N-desmethyltramadol	N.A.	Drug Toxicity	Genotype TT is associated with increased concentrations of n-desmethyltramadol in people with Death as compared to genotypes CC + CT.		[ 50]
Cyclophosphamide	N.A.	Neutropenia	Genotype TT is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 52]
Doxorubicin	N.A.	Neutropenia	Genotype TT is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 52]
Fluorouracil	N.A.	Neutropenia	Genotype TT is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 52]
Carbamazepine	N.A.	Epilepsy	Patients with the TT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.		[ 71]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Patients with the TT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.		[ 68]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotype TT is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 52]
Doxorubicin	N.A.	Breast Neoplasms	Genotype TT is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 52]
Fluorouracil	N.A.	Breast Neoplasms	Genotype TT is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 52]
Mycophenolic Acid	N.A.	Organ Transplantation	Patients with the TT genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.		[ 65]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the TT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.		[ 33]
Antiepileptics	N.A.	Epilepsy	Genotype TT is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.		[ 60]
Antiepileptics	N.A.	Epilepsy	Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 18]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:         23 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the decreased drug dose in patients (compare with genotype CC); Correlated with the increased drug dose-adjusted trough concentrations in patients (compare with genotype CC)		[ 88]
Carbamazepine	Drug Info	Epilepsy	Correlated with the decreased drug metabolism in patients (compare with genotype CC)		[ 71]
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased nausea risk in patients (compare with genotype CC)		[ 52]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased nausea risk in patients (compare with genotype CC)		[ 52]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased nausea risk in patients (compare with genotype CC)		[ 52]
Carbamazepine	N.A.	Neurotoxicity Syndromes	Genotypes CT + TT are associated with decreased metabolism of carbamazepine in men with Epilepsy as compared to genotype CC.		[ 71]
Antiepileptics	N.A.	Neurotoxicity Syndromes	Genotypes CT + TT are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.		[ 18]
Antiepileptics	N.A.	Neutropenia	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.		[ 42]
Tacrolimus	N.A.	Kidney Tubular Necrosis, Acute	Genotypes CT + TT is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 88]
Tenofovir	N.A.	Bone Marrow Disorder	Genotypes CT + TT is not associated with concentrations of tenofovir in people with HIV Infections as compared to genotype CC.		[ 73]
Cyclosporine	N.A.	Transplant Rejection	Genotypes CT + TT are not associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 13]
Mycophenolate Mofetil	N.A.	Transplant Rejection	Genotypes CT + TT are not associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 13]
Cyclophosphamide	N.A.	Nausea	Genotypes CT + TT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.		[ 52]
Doxorubicin	N.A.	Nausea	Genotypes CT + TT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.		[ 52]
Fluorouracil	N.A.	Nausea	Genotypes CT + TT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.		[ 52]
Carbamazepine	N.A.	Epilepsy	Genotypes CT + TT are associated with decreased metabolism of carbamazepine in men with Epilepsy as compared to genotype CC.		[ 71]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotypes CT + TT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.		[ 52]
Doxorubicin	N.A.	Breast Neoplasms	Genotypes CT + TT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.		[ 52]
Fluorouracil	N.A.	Breast Neoplasms	Genotypes CT + TT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.		[ 52]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 88]
Antiepileptics	N.A.	Epilepsy	Genotypes CT + TT are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.		[ 18]
Antiepileptics	N.A.	Epilepsy	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.		[ 42]
Antiepileptics	N.A.	Epilepsy	Correlated with the increased drug resistance in patients (compare with genotype CC); Irrelevant to the increased drug resistance in patients (compare with genotype CC)		[ 18], [ 42]
Genetic Polymorphism	rs717620
Site of GPD	chr10:99782821 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1350/676 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         20 Drugs in Total
Methotrexate	Drug Info	Leukemia	Irrelevant to the nephrotoxicity risk in patients (compare with Allele T); Irrelevant to the prolonged high drug concentrations risk patients (compare with Allele T)		[ 89]
Mycophenolic Acid	N.A.	Primary Graft Failure	Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T.		[ 90]
Mycophenolic Acid	N.A.	Kidney Tubular Necrosis, Acute	Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T.		[ 90]
Tacrolimus	N.A.	Primary Graft Failure	Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T.		[ 90]
Tacrolimus	N.A.	Kidney Tubular Necrosis, Acute	Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T.		[ 90]
Raltegravir	N.A.	Kidney Tubular Necrosis, Acute	Allele C is not associated with concentration of raltegravir in people with HIV Infections as compared to allele T.		[ 91]
Methotrexate	N.A.	Kidney Tubular Necrosis, Acute	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 17]
Methotrexate	N.A.	Nephrotoxicity	Allele C is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.		[ 89]
Methotrexate	N.A.	Nephrotoxicity	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 89]
Talinolol	N.A.	Mucositis	Allele C is not associated with clearance of talinolol in healthy individuals as compared to allele T.		[ 25]
Antiepileptics	N.A.	Kidney Disorder	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 30]
Platinum Compounds	N.A.	Drug Toxicity	Allele C is not associated with severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.		[ 34]
Mycophenolic Acid	N.A.	Peripheral Nervous System Diseases	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.		[ 41]
Antiepileptics	N.A.	Epilepsy	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 30]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 89]
Methotrexate	N.A.	Lymphoid Leukemia	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 89]
Methotrexate	N.A.	Leukemia	Allele C is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.		[ 89]
Methotrexate	N.A.	Lymphoma	Allele C is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.		[ 89]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.		[ 89]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the drug resistance in patients (compare with Allele T)		[ 30]
Allele T	Click to Show/Hide the Full List of Affected Drugs:         58 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with Allele C); Correlated with the increased drug toxicity risk in patients (compare with Allele C )		[ 81]
Mycophenolic acid	Drug Info	Kidney Transplantation	Correlated with the drug exposure in patients (compare with allele C)		[ 14]
Lopinavir	Drug Info	HIV Infection	Correlated with the increased drug toxicity risk (compare with Genotype CC)		[ 94]
Ritonavir	Drug Info	HIV Infection	Correlated with the increased drug toxicity risk (compare with Genotype CC)		[ 94]
Tenofovir	Drug Info	HIV Infection	Correlated with the increased drug toxicity risk (compare with Genotype CC); Irrelevant to the likelihood of kidney diseases in patients (compare with allele C)		[ 16], [ 94]
Atazanavir	Drug Info	HIV Infection	Correlated with the increased drug toxicity risk (compare with Genotype CC)		[ 94]
Pitavastatin	N.A.	Drug Toxicity	Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.		[ 19]
Diclofenac	N.A.	Toxic Liver Disease	Allele T is associated with increased likelihood of Toxic liver disease when treated with diclofenac as compared to allele C.		[ 97]
Methotrexate	N.A.	Toxic Liver Disease	Allele T is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 81]
Mycophenolate Mofetil	N.A.	Febrile Neutropenia	Allele T is not associated with variation in mycophenolic acid pharmacokinetic parameters when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.		[ 61]
Methotrexate	N.A.	Drug Toxicity	Allele T is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 81]
Lacosamide	N.A.	Progression-free Survival	Allele T is associated with decreased exposure to lacosamide in children with Epilepsy as compared to allele C.		[ 99]
Carbamazepine	N.A.	Graft Vs Host Disease	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.		[ 22]
Mycophenolate Mofetil	N.A.	Neurotoxicity Syndromes	Allele T is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.		[ 21]
Cisplatin	N.A.	Kidney Tubular Necrosis, Acute	Allele T is not associated with response rate, progression-free survival, or overall survival when treated with cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 23]
Gemcitabine	N.A.	Kidney Tubular Necrosis, Acute	Allele T is not associated with response rate, progression-free survival, or overall survival when treated with cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 23]
Vincristine	N.A.	Peripheral Nervous System Diseases	Allele T is not associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 103]
Methotrexate	N.A.	Mucositis	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 24]
Lacosamide	N.A.	Mucositis	Allele T is associated with increased resistance to lacosamide in children with Epilepsy as compared to allele C.		[ 26]
Mycophenolic Acid	N.A.	Decreased Glomerular Filtration Rate	Allele T is associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele C.		[ 14]
Tenofovir	N.A.	Kidney Disorder	Allele T is not associated with likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele C.		[ 16]
Methotrexate	N.A.	Kidney Disorder	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 28]
Methotrexate	N.A.	Drug Toxicity	Allele T is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.		[ 31]
Methotrexate	N.A.	Nausea	Allele T is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.		[ 31]
Imatinib	N.A.	Leukopenia	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 108]
Doxorubicin	N.A.	Drug Toxicity	Allele T is not associated with decreased response to doxorubicin in people with Breast Neoplasms as compared to allele C.		[ 109]
Methotrexate	N.A.	Transplant Rejection	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 36]
Imatinib	N.A.	Drug Toxicity	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 108]
Imatinib	N.A.	Discontinuation	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 108]
Antiepileptics	N.A.	Toxic Liver Disease	Allele T is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele C.		[ 18]
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 77]
Atazanavir	N.A.	Drug Toxicity	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.		[ 94]
Lopinavir	N.A.	Drug Toxicity	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.		[ 94]
Ritonavir	N.A.	Drug Toxicity	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.		[ 94]
Tenofovir	N.A.	Drug Toxicity	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.		[ 94]
Atorvastatin	N.A.	Progression-free Survival	Allele T is associated with decreased dose of atorvastatin and simvastatin.		[ 113]
Simvastatin	N.A.	Progression-free Survival	Allele T is associated with decreased dose of atorvastatin and simvastatin.		[ 113]
Adefovir Dipivoxil	N.A.	Nephrotoxicity	Allele T is not associated with increased risk of nephrotoxicity when treated with adefovir dipivoxil in people with Hepatitis B as compared to allele C.		[ 114]
Atazanavir	N.A.	Beta-thalassemia And Related Diseases	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.		[ 94]
Lopinavir	N.A.	Beta-thalassemia And Related Diseases	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.		[ 94]
Ritonavir	N.A.	Beta-thalassemia And Related Diseases	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.		[ 94]
Tenofovir	N.A.	Beta-thalassemia And Related Diseases	Allele T is associated with increased risk of Drug Toxicity when treated with atazanavir, lopinavir, ritonavir or tenofovir as compared to genotype CC.		[ 94]
Antiepileptics	N.A.	Epilepsy	Allele T is not associated with number of seizures per year when treated with antiepileptics in people with Drug Resistance as compared to allele C.		[ 18]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 28]
Methotrexate	N.A.	Lymphoid Leukemia	Allele T is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 28]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 81]
Methotrexate	N.A.	Lymphoid Leukemia	Allele T is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 81]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 36]
Methotrexate	N.A.	Lymphoid Leukemia	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 36]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 24]
Methotrexate	N.A.	Leukemia	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 24]
Methotrexate	N.A.	Lymphoma	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 24]
Methotrexate	N.A.	Osteosarcoma	Allele T is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 24]
Methotrexate	N.A.	Leukemia	Allele T is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 81]
Methotrexate	N.A.	Lymphoma	Allele T is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 81]
Methotrexate	N.A.	Osteosarcoma	Allele T is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 81]
Tenofovir	N.A.	HIV Infectious Disease	Allele T is not associated with likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele C.		[ 16]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the number of seizures per year in patients (compare with allele C)		[ 18]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         49 Drugs in Total
Fluorouracil	Drug Info	Colonic Neoplasm	Correlated with the increased drug toxicity risk in patients (compare with Genotypes CT + TT)		[ 100]
Leucovorin	Drug Info	Colonic Neoplasm	Correlated with the increased drug toxicity risk in patients (compare with Genotypes CT + TT)		[ 100]
Oxaliplatin	Drug Info	Colonic Neoplasm	Correlated with the increased drug toxicity risk in patients (compare with Genotypes CT + TT)		[ 100]
Sorafenib	Drug Info	Renal Cell Carcinoma	Correlated with the increased exanthema risk in patients (compare with genotype Ct)		[ 101]
Tenofovir	Drug Info	HIV Infection	Correlated with the increased kidney tubular dysfunction risk in patients (compare with Genotypes CT + TT); Irrelevant to the increased renal proximal tubulopathy risk in patients (compare with Genotypes CT + TT)		[ 4], [ 5]
Clopidogrel	N.A.	Neurotoxicity Syndromes	Genotype CC is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.		[ 47]
Mycophenolic Acid	N.A.	Leukopenia	Genotype CC is not associated with any pharmacokinetic parameters measured in the study when exposed to mycophenolic acid as compared to genotype TT.		[ 65]
Sorafenib	N.A.	Exanthema	Genotype CC is associated with increased risk of Exanthema when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CT.		[ 101]
Lacosamide	N.A.	Mucositis	Genotype CC is associated with increased concentrations of lacosamide in children with Epilepsy as compared to genotypes CT + TT.		[ 26]
Irinotecan	N.A.	Neutropenia	Genotype CC is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.		[ 68]
Irinotecan	N.A.	Diarrhea	Genotype CC is not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.		[ 68]
Tenofovir	N.A.	Nephrotoxicity	Genotype CC is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to genotypes CT + TT.		[ 4]
Tenofovir	N.A.	Nephrotoxicity	Genotype CC is associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to genotypes CT + TT.		[ 5]
Mycophenolic Acid	N.A.	Neurotoxicity Syndromes	Genotype CC is not associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotype CT.		[ 108]
Fluorouracil	N.A.	Drug Toxicity	Genotype CC is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.		[ 100]
Leucovorin	N.A.	Drug Toxicity	Genotype CC is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.		[ 100]
Oxaliplatin	N.A.	Drug Toxicity	Genotype CC is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.		[ 100]
Atorvastatin	N.A.	HIV Infectious Disease	Patients with the CC genotype may have increased dose of simvastatin and atorvastatin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the dose of simvastatin.		[ 98]
Simvastatin	N.A.	HIV Infectious Disease	Patients with the CC genotype may have increased dose of simvastatin and atorvastatin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the dose of simvastatin.		[ 98]
Erythromycin	N.A.	Beta-thalassemia And Related Diseases	Patients with the CC genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.		[ 110]
Atazanavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Lopinavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Ritonavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Tenofovir	N.A.	Beta-thalassemia And Related Diseases	Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Fluorouracil	N.A.	Colonic Neoplasms	Genotype CC is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.		[ 100]
Leucovorin	N.A.	Colonic Neoplasms	Genotype CC is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.		[ 100]
Oxaliplatin	N.A.	Colonic Neoplasms	Genotype CC is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.		[ 100]
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the CC genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.		[ 87]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the CC genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.		[ 87]
Oxaliplatin	N.A.	Colorectal Neoplasms	Patients with the CC genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.		[ 87]
Cisplatin	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 CC genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Doxorubicin	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 CC genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 CC genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Antiepileptics	N.A.	Epilepsy	Patients with the CC genotype and Epilepsy who are treated with antiepileptics may be less likely to be resistant to treatment as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 30]
Pitavastatin	N.A.	Breast Neoplasms	Patients with the CC genotype may have increased exposure to pitavastatin as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		[ 19]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Pediatric patients with major thalassemia and the CC genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the CT or TT genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.		[ 116]
Atorvastatin	N.A.	Hypercholesterolemia	Men with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a greater decrease in triglycerides as compared to men with either the CT or TT genotypes. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.		[ 117]
Tamoxifen	N.A.	Breast Neoplasms	Patients with the CC genotype and breast neoplasms may have reduced disease-free survival when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.		[ 118]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.		[ 119]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs717620 CC genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 120]
Methotrexate	N.A.	Lymphoid Leukemia	The current evidence base suggests that there is no significant association between the rs717620 CC genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 120]
Methotrexate	N.A.	Leukemia	Patients with the rs717620 CC genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 120]
Methotrexate	N.A.	Lymphoma	Patients with the rs717620 CC genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 120]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs717620 CC genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 120]
Tenofovir	N.A.	HIV Infectious Disease	Genotype CC is associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to genotypes CT + TT.		[ 5]
Tenofovir	N.A.	HIV Infectious Disease	Genotype CC is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to genotypes CT + TT.		[ 4]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV infection who are treated with tenofovir may have an increased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.		[ 58]
Mycophenolic Acid	N.A.	Kidney Transplantation	Genotype CC is associated with increased exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotypes CT + TT.		[ 108]
Tacrolimus	N.A.	Kidney Transplantation	Genotype CC is associated with increased exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotypes CT + TT.		[ 108]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         43 Drugs in Total
Tamoxifen	Drug Info	Breast Neoplasm	Correlated with the increased drug response in patients (compare with genotype CC)		[ 106]
Tamoxifen	N.A.	Drug Toxicity	Genotype CT is not associated with risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotype CC.		[ 78]
Tamoxifen	N.A.	Neurotoxicity Syndromes	Genotype CT is associated with increased response to tamoxifen in women Breast Neoplasms as compared to genotype CC.		[ 106]
Paclitaxel	N.A.	Progression-free Survival	Genotype CT is associated with decreased dose of paclitaxel in people with Peripheral Nervous System Diseases as compared to genotype CC.		[ 111]
Deferasirox	N.A.	Acidosis	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Dehydration	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Fever	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Myoclonus	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Trismus	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Uremia	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Vomiting	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Drug Toxicity	Genotype CT is associated with increased severity of Drug Toxicity when treated with deferasirox in children with Beta-thalassemia and related diseases as compared to genotype CC.		[ 64]
Sorafenib	N.A.	Exanthema	Patients with the CT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.		[ 101]
Atorvastatin	N.A.	HIV Infectious Disease	Patients with the CT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.		[ 98]
Simvastatin	N.A.	HIV Infectious Disease	Patients with the CT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.		[ 98]
Erythromycin	N.A.	Beta-thalassemia And Related Diseases	Patients with the CT genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.		[ 103]
Atazanavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Lopinavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Ritonavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Tenofovir	N.A.	Beta-thalassemia And Related Diseases	Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Fluorouracil	N.A.	Colonic Neoplasms	Patients with the CT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.		[ 100]
Leucovorin	N.A.	Colonic Neoplasms	Patients with the CT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.		[ 100]
Oxaliplatin	N.A.	Colonic Neoplasms	Patients with the CT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.		[ 100]
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the CT genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.		[ 87]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the CT genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.		[ 87]
Oxaliplatin	N.A.	Colorectal Neoplasms	Patients with the CT genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes.		[ 87]
Cisplatin	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 CT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Doxorubicin	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 CT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 CT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Antiepileptics	N.A.	Epilepsy	Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 30]
Pitavastatin	N.A.	Breast Neoplasms	Patients with the CT genotype may have increased exposure to pitavastatin as compared to patients with the TT genotype, but decreased exposure as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		[ 19]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Genotype CT is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Atorvastatin	N.A.	Hypercholesterolemia	Men with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.		[ 105]
Tamoxifen	N.A.	Breast Neoplasms	Genotype CT is associated with increased response to tamoxifen in women Breast Neoplasms as compared to genotype CC.		[ 106]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the CT genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.		[ 107]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs717620 CT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 108]
Methotrexate	N.A.	Lymphoid Leukemia	The current evidence base suggests that there is no significant association between the rs717620 CT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 108]
Methotrexate	N.A.	Leukemia	Patients with the rs717620 CT genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with TT genotypes, and an increased risk of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 108]
Methotrexate	N.A.	Lymphoma	Patients with the rs717620 CT genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with TT genotypes, and an increased risk of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 108]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs717620 CT genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with TT genotypes, and an increased risk of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 108]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.		[ 58]
Mycophenolic Acid	N.A.	Kidney Transplantation	Patients with the rs717620 CT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.		[ 102]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the rs717620 CT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.		[ 102]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         45 Drugs in Total
Erythromycin	Drug Info	Bacterial Infections	Correlated with the increased drug metabolism (compare with genotypes CC + CT)		[ 103]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased severity of neurotoxicity syndromes in patients (compare with genotypes CC + CT)		[ 87]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased severity of neurotoxicity syndromes in patients (compare with genotypes CC + CT)		[ 87]
Oxaliplatin	Drug Info	Colorectal Neoplasm	Correlated with the increased severity of neurotoxicity syndromes in patients (compare with genotypes CC + CT)		[ 87]
Efavirenz	Drug Info	HIV Infection	Correlated with the increased drug concentrations in patients (compare with genotypes CC + CT)		[ 107]
Fluorouracil	N.A.	Neurotoxicity Syndromes	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 87]
Leucovorin	N.A.	Neurotoxicity Syndromes	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 87]
Oxaliplatin	N.A.	Neurotoxicity Syndromes	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 87]
Methotrexate	N.A.	Leukopenia	Genotype TT is not associated with basal urinary coproporphyrin I/ (I+III) ratio when treated with methotrexate in people with Lymphoma as compared to genotype CC.		[ 48]
Trabectedin	N.A.	Toxic Liver Disease	Genotype TT is associated with Toxic liver disease when treated with trabectedin in men with Sarcoma.		[ 114]
Mycophenolic Acid	N.A.	Drug Toxicity	Genotype TT is associated with increased dose-adjusted trough concentrations of mycophenolic acid in people with Kidney Transplantation as compared to genotypes CC + CT.		[ 115]
Efavirenz	N.A.	Peripheral Nervous System Diseases	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT.		[ 107]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Genotype TT is associated with increased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotypes CC + CT.		[ 38]
Erythromycin	N.A.	Vomiting	Genotype TT is associated with increased metabolism of erythromycin as compared to genotypes CC + CT.		[ 103]
Sorafenib	N.A.	Exanthema	Patients with the TT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.		[ 101]
Atorvastatin	N.A.	HIV Infectious Disease	Patients with the TT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.		[ 98]
Simvastatin	N.A.	HIV Infectious Disease	Patients with the TT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.		[ 98]
Atazanavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Lopinavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Ritonavir	N.A.	Beta-thalassemia And Related Diseases	Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Tenofovir	N.A.	Beta-thalassemia And Related Diseases	Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.		[ 92]
Fluorouracil	N.A.	Colonic Neoplasms	Patients with the TT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.		[ 100]
Leucovorin	N.A.	Colonic Neoplasms	Patients with the TT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.		[ 100]
Oxaliplatin	N.A.	Colonic Neoplasms	Patients with the TT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia.		[ 100]
Fluorouracil	N.A.	Colorectal Neoplasms	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 87]
Leucovorin	N.A.	Colorectal Neoplasms	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 87]
Oxaliplatin	N.A.	Colorectal Neoplasms	Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.		[ 87]
Cisplatin	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 TT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Doxorubicin	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 TT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Patients with osteosarcoma and the rs717620 TT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate.		[ 12]
Antiepileptics	N.A.	Epilepsy	Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 30]
Pitavastatin	N.A.	Breast Neoplasms	Patients with the TT genotype may have decreased exposure to pitavastatin as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.		[ 19]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.		[ 104]
Atorvastatin	N.A.	Hypercholesterolemia	Men with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atrovastatin.		[ 105]
Tamoxifen	N.A.	Breast Neoplasms	No patients with the TT genotype were included in analysis of the association between genotype and disease-free survival in response to tamoxifen treatment in patients with breast neoplasms.		[ 106]
Efavirenz	N.A.	HIV Infectious Disease	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT.		[ 107]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs717620 TT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 108]
Methotrexate	N.A.	Lymphoid Leukemia	The current evidence base suggests that there is no significant association between the rs717620 TT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 108]
Methotrexate	N.A.	Leukemia	Patients with the rs717620 TT genotype who are administered methotrexate may have an increased risk of drug toxicity as compared to patients with the CT or CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 108]
Methotrexate	N.A.	Lymphoma	Patients with the rs717620 TT genotype who are administered methotrexate may have an increased risk of drug toxicity as compared to patients with the CT or CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 108]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs717620 TT genotype who are administered methotrexate may have an increased risk of drug toxicity as compared to patients with the CT or CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate.		[ 108]
Tenofovir	N.A.	HIV Infectious Disease	Genotype TT is associated with increased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotypes CC + CT.		[ 38]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.		[ 58]
Mycophenolic Acid	N.A.	Kidney Transplantation	Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.		[ 102]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the rs717620 TT genotype and kidney transplantation who are treated with mycophenolic acid and tacrolimus may have decreased exposure to mycophenolic acid as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs717620 and mycophenolic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence mycophenolic acid exposure.		[ 102]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:         44 Drugs in Total
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased drug response in patients (compare with genotype CC)		[ 105]
Methotrexate	Drug Info	Lymphoid	Correlated with the increased drug clearance in patients (compare with genotype CC)		[ 7]
Leucovorin	Drug Info	Leukemia	Correlated with the increased drug distribution volume in patients (compare with genotype CC)		[ 7]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the drug response in patients (compare with genotype CC)		[ 69]
Tenofovir	Drug Info	HIV Infection	Irrelevant to the glomerular disease in patients (compare with genotype CC)		[ 58]
Methotrexate	N.A.	Cardiotoxicity	Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.		[ 116]
Antiepileptics	N.A.	Neurotoxicity Syndromes	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.		[ 70]
Antiepileptics	N.A.	Neurotoxicity Syndromes	Genotypes CT + TT are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.		[ 18]
Methotrexate	N.A.	Leukopenia	Genotypes CT + TT are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 108]
Methotrexate	N.A.	Neutropenia	Genotypes CT + TT are not associated with risk of Neutropenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 108]
Tenofovir	N.A.	Kidney Disorder	Genotypes CT + TT are not associated with Kidney Disorder when exposed to tenofovir in people with HIV infectious disease as compared to genotype CC.		[ 58]
Carbamazepine	N.A.	Leukopenia	Genotypes CT + TT is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype CC.		[ 69]
Simvastatin	N.A.	Kidney Tubular Necrosis, Acute	Genotypes CT + TT is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotype CC.		[ 120]
Tacrolimus	N.A.	Kidney Tubular Necrosis, Acute	Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 88]
Methotrexate	N.A.	Kidney Tubular Necrosis, Acute	Genotypes CT + TT are associated with increased clearance of methotrexate in people with Lymphoma as compared to genotype CC.		[ 7]
Atorvastatin	N.A.	Mucositis	Genotypes CT + TT are not associated with response to atorvastatin in men with Hypercholesterolemia as compared to genotype CC.		[ 105]
Methotrexate	N.A.	Mucositis	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 108]
Voriconazole	N.A.	Mucositis	Genotypes CT + TT is associated with increased trough concentration of voriconazole in children as compared to genotype CC.		[ 122]
Cisplatin	N.A.	Neutropenia	Genotypes CT + TT is associated with increased severity of Neutropenia when treated with cisplatin, docetaxel and fluorouracil in people with Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Adenosquamous or Esophageal Neoplasms as compared to genotype CC.		[ 123]
Docetaxel	N.A.	Neutropenia	Genotypes CT + TT is associated with increased severity of Neutropenia when treated with cisplatin, docetaxel and fluorouracil in people with Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Adenosquamous or Esophageal Neoplasms as compared to genotype CC.		[ 123]
Fluorouracil	N.A.	Neutropenia	Genotypes CT + TT is associated with increased severity of Neutropenia when treated with cisplatin, docetaxel and fluorouracil in people with Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Adenosquamous or Esophageal Neoplasms as compared to genotype CC.		[ 123]
Tenofovir	N.A.	Bone Marrow Disorder	Genotypes CT + TT is not associated with concentrations of tenofovir in people with HIV Infections as compared to genotype CC.		[ 73]
Tenofovir	N.A.	Toxic Liver Disease	Genotypes CT + TT is not associated with increased discontinuation of tenofovir in people with HIV Infections as compared to genotype CC.		[ 75]
Leucovorin	N.A.	Toxic Liver Disease	Genotypes CT + TT are associated with increased distribution volume when treated with leucovorin and methotrexate in people with Lymphoma as compared to genotype CC.		[ 7]
Cisplatin	N.A.	Peripheral Nervous System Diseases	Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.		[ 12]
Doxorubicin	N.A.	Peripheral Nervous System Diseases	Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.		[ 12]
Methotrexate	N.A.	Peripheral Nervous System Diseases	Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.		[ 12]
Methotrexate	N.A.	Drug Toxicity	Genotypes CT + TT is associated with increased likelihood of Drug Toxicity methotrexate in children with Acute lymphoblastic leukemia as compared to genotype CC.		[ 127]
Cisplatin	N.A.	Osteosarcoma	Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.		[ 12]
Doxorubicin	N.A.	Osteosarcoma	Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.		[ 12]
Antiepileptics	N.A.	Epilepsy	Genotypes CT + TT are not associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.		[ 18]
Antiepileptics	N.A.	Epilepsy	Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.		[ 42]
Antiepileptics	N.A.	Epilepsy	Genotypes CT + TT is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype CC.		[ 69]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes CT + TT are associated with decreased response to atorvastatin in men with Hypercholesterolemia as compared to genotype CC.		[ 105]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 108]
Methotrexate	N.A.	Lymphoid Leukemia	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 108]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CT + TT are associated with increased clearance of methotrexate in people with Lymphoma as compared to genotype CC.		[ 7]
Methotrexate	N.A.	Lymphoid Leukemia	Genotypes CT + TT are associated with increased clearance of methotrexate in people with Lymphoma as compared to genotype CC.		[ 7]
Methotrexate	N.A.	Leukemia	Genotypes CT + TT are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 108]
Methotrexate	N.A.	Lymphoma	Genotypes CT + TT are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 108]
Methotrexate	N.A.	Osteosarcoma	Genotypes CT + TT are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 108]
Tenofovir	N.A.	HIV Infectious Disease	Genotypes CT + TT are not associated with Kidney Disorder when exposed to tenofovir in people with HIV infectious disease as compared to genotype CC.		[ 58]
Antiepileptics	N.A.	Epilepsy	Correlated with the increased drug resistance in patients (compare with genotype CC); Irrelevant to the increased drug resistance in patients (compare with genotype CC)		[ 18], [ 42], [ 70]
Genetic Polymorphism	rs7917432
Site of GPD	chr10:68399112 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.3087/1546 (Global)
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tenofovir	Drug Info	HIV Infection	Correlated with the decreased drug clearance in patients (compare with genotype CC)		[ 15]
Tenofovir	N.A.	Decreased Glomerular Filtration Rate	Genotype CT is associated with increased likelihood of Decreased glomerular filtration rate when treated with tenofovir in people with HIV infectious disease as compared to genotype CC.		[ 15]
Tenofovir	N.A.	HIV Infectious Disease	Genotype CT is associated with increased likelihood of Decreased glomerular filtration rate when treated with tenofovir in people with HIV infectious disease as compared to genotype CC.		[ 15]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.		[ 15]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.		[ 15]
Genetic Polymorphism	rs8187707
Site of GPD	chr10:99850776 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0310/155 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tenofovir	Drug Info	HIV Infection	Correlated with the decreased drug clearance in patients (compare with genotype CC)		[ 15]
Tenofovir	N.A.	Decreased Glomerular Filtration Rate	Allele T is associated with increased likelihood of Decreased glomerular filtration rate when treated with tenofovir in people with HIV infectious disease as compared to genotype CC.		[ 15]
Tenofovir	N.A.	HIV Infectious Disease	Allele T is associated with increased likelihood of Decreased glomerular filtration rate when treated with tenofovir in people with HIV infectious disease as compared to genotype CC.		[ 15]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Trabectedin	N.A.	Toxic Liver Disease	Genotype CT is associated with Toxic liver disease when treated with trabectedin in men with Sarcoma.		[ 110]
Tenofovir	N.A.	HIV Infectious Disease	Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.		[ 15]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.		[ 15]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.		[ 15]
Genetic Polymorphism	rs8187710
Site of GPD	chr10:99851537 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.0679/340 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:         25 Drugs in Total
Lopinavir	Drug Info	HIV Infection	Correlated with the higher drug accumulation in patients (compare with genotype GG)		[ 117]
Doxorubicin	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased cardiotoxicity risk in patients (compare with allele G)		[ 6]
Calcein	N.A.	Cardiotoxicity	Allele A is associated with decreased transport of when exposed to calcein or lopinavir.		[ 119]
Lopinavir	N.A.	Cardiotoxicity	Allele A is associated with decreased transport of when exposed to calcein or lopinavir.		[ 119]
Rosuvastatin	N.A.	Nausea	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.		[ 82]
Cisplatin	N.A.	Kidney Tubular Necrosis, Acute	Allele A is not associated with clearance of unbound cisplatin when treated with cisplatin in people with Neoplasms as compared to allele G.		[ 23]
Gemcitabine	N.A.	Kidney Tubular Necrosis, Acute	Allele A is not associated with response rate, progression-free survival, or overall survival when treated with cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.		[ 23]
Methotrexate	N.A.	Kidney Tubular Necrosis, Acute	Allele A is not associated with clearance of methotrexate in people with Lymphoma.		[ 7]
Pravastatin	N.A.	Mucositis	Allele A is not associated with pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to allele G.		[ 8]
Doxorubicin	N.A.	Mucositis	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.		[ 6]
Tenofovir	N.A.	Fanconi Renotubular Syndrome	Allele A is not associated with increased risk of Fanconi Syndrome when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 15]
Tenofovir	N.A.	Nausea	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 4]
Cyclophosphamide	N.A.	Peripheral Nervous System Diseases	Allele A is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele G.		[ 10]
Epirubicin	N.A.	Peripheral Nervous System Diseases	Allele A is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele G.		[ 10]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele A is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele G.		[ 10]
Tenofovir	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 5]
Lopinavir	N.A.	Vomiting	Allele A is associated with a higher accumulation of lopinavir in peripheral blood mononuclear cells when treated with lopinavir in people with HIV Infections as compared to genotype GG.		[ 117]
Tenofovir	N.A.	Fanconi Renotubular Syndrome	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 4]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 4]
Tenofovir	N.A.	Fanconi Renotubular Syndrome	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 5]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 5]
Tenofovir	N.A.	HIV Infectious Disease	Allele A is not associated with increased risk of Fanconi Syndrome when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 15]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.		[ 6]
Lopinavir	N.A.	HIV Infectious Disease	Allele A is associated with decreased transport of when exposed to calcein or lopinavir.		[ 119]
Lopinavir	N.A.	HIV Infectious Disease	Allele A is associated with a higher accumulation of lopinavir in peripheral blood mononuclear cells when treated with lopinavir in people with HIV Infections as compared to genotype GG.		[ 117]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Chop	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with increased likelihood of Cardiotoxicity when treated with CHOP and rituximab in people with Non-Hodgkin Lymphoma as compared to genotype GG.		[ 119]
Rituximab	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with increased likelihood of Cardiotoxicity when treated with CHOP and rituximab in people with Non-Hodgkin Lymphoma as compared to genotype GG.		[ 119]
Chop	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with decreased response to CHOP and rituximab in people with Non-Hodgkin Lymphoma as compared to genotype GG.		[ 119]
Rituximab	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with decreased response to CHOP and rituximab in people with Non-Hodgkin Lymphoma as compared to genotype GG.		[ 119]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Trabectedin	N.A.	Toxic Liver Disease	Genotype AG is associated with Toxic liver disease when treated with trabectedin in men with Sarcoma.		[ 110]
Deferasirox	N.A.	Acidosis	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Dehydration	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Fever	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Myoclonus	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Trismus	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Uremia	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Deferasirox	N.A.	Vomiting	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Tenofovir	N.A.	Fanconi Renotubular Syndrome	The current evidence base suggests that there is no significant association between the rs8187710 AG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.		[ 4]
Tenofovir	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no significant association between the rs8187710 AG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.		[ 4]
Calcein	N.A.	Epilepsy	The AG genotype was not studied.		[ 118]
Lopinavir	N.A.	Epilepsy	The AG genotype was not studied.		[ 118]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.		[ 6]
Lopinavir	N.A.	HIV Infectious Disease	Patients with the AG genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.		[ 118]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Genotype AG is associated with increased risk of Myoclonus, Trismus, Acidosis, Dehydration, Fever, Uremia and Vomiting when treated with deferasirox in children with beta-Thalassemia.		[ 104]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Lumefantrine	N.A.	Fanconi Renotubular Syndrome	Genotype AA is associated with increased concentrations of lumefantrine in children with Malaria as compared to genotypes AG + GG.		[ 120]
Tenofovir	N.A.	Fanconi Renotubular Syndrome	The current evidence base suggests that there is no significant association between the rs8187710 AA genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.		[ 4]
Tenofovir	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no significant association between the rs8187710 AA genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.		[ 4]
Calcein	N.A.	Epilepsy	Patients with the AA genotype may have higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir as compared to the patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.		[ 118]
Lopinavir	N.A.	Epilepsy	Patients with the AA genotype may have higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir as compared to the patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.		[ 118]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.		[ 6]
Lopinavir	N.A.	HIV Infectious Disease	Patients with the AA genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.		[ 118]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.		[ 104]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Tenofovir	N.A.	Fanconi Renotubular Syndrome	The current evidence base suggests that there is no significant association between the rs8187710 GG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.		[ 4]
Tenofovir	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no significant association between the rs8187710 GG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir.		[ 4]
Calcein	N.A.	Epilepsy	Patients with the GG genotype may have lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir as compared to the patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.		[ 118]
Lopinavir	N.A.	Epilepsy	Patients with the GG genotype may have lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir as compared to the patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.		[ 118]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.		[ 6]
Lopinavir	N.A.	HIV Infectious Disease	Patients with the GG genotype who are treated with lopinavir may have a lower accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.		[ 118]
Deferasirox	N.A.	Beta-thalassemia And Related Diseases	Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AA or AG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox.		[ 104]
Genetic Polymorphism	rs4148386
Site of GPD	chr10:99788711 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.3886/1946 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Carbamazepine	Drug Info	Epilepsy	Correlated with the increased drug clearance in patients (compare with genotype GG)		[ 71]
Carbamazepine	N.A.	Neurotoxicity Syndromes	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.		[ 71]
Carbamazepine	N.A.	Epilepsy	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.		[ 71]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Carbamazepine	N.A.	Epilepsy	Patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.		[ 71]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Carbamazepine	N.A.	Epilepsy	Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.		[ 71]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Carbamazepine	N.A.	Epilepsy	Patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.		[ 71]
Genetic Polymorphism	rs533334893
Site of GPD	chr10:99792360 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=1.0000/1979 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Vincristine	N.A.	Drug Toxicity	Genotype AA is associated with increased severity of Drug Toxicity when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma and dubin-johnson syndrome.		[ 121]
Genetic Polymorphism	rs8187692
Site of GPD	chr10:99836218 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	G=0.9660/1911 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Drug Toxicity	Allele A is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.		[ 82]
Genetic Polymorphism	rs1885301
Site of GPD	chr10:99781296 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.3952/1979 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Pitavastatin	N.A.	Drug Toxicity	Allele A is not associated with exposure to pitavastatin in healthy individuals as compared to allele G.		[ 19]
Cisplatin	N.A.	Kidney Tubular Necrosis, Acute	Allele A is not associated with response rate, progression-free survival, or overall survival when treated with cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.		[ 23]
Gemcitabine	N.A.	Kidney Tubular Necrosis, Acute	Allele A is not associated with response rate, progression-free survival, or overall survival when treated with cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.		[ 23]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Folfiri	N.A.	Nausea	Genotype AA is associated with increased severity of Nausea when treated with FOLFIRI in people with Colorectal Neoplasms as compared to genotypes AG + GG.		[ 67]
Fluorouracil	N.A.	Neurotoxicity Syndromes	Genotype AA is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.		[ 87]
Leucovorin	N.A.	Neurotoxicity Syndromes	Genotype AA is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.		[ 87]
Oxaliplatin	N.A.	Neurotoxicity Syndromes	Genotype AA is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.		[ 87]
Genetic Polymorphism	rs17216177
Site of GPD	chr10:99843765 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.9270/1834 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Rosuvastatin	N.A.	Drug Toxicity	Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele T.		[ 82]
Cisplatin	N.A.	Kidney Tubular Necrosis, Acute	Allele C is not associated with response rate, progression-free survival, or overall survival when treated with cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.		[ 23]
Gemcitabine	N.A.	Kidney Tubular Necrosis, Acute	Allele C is not associated with response rate, progression-free survival, or overall survival when treated with cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.		[ 23]
Genetic Polymorphism	rs7899457
Site of GPD	chr10:99845746 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9670/1913 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Drug Toxicity	Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.		[ 82]
Genetic Polymorphism	rs8187706
Site of GPD	chr10:99850698 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.9640/1907 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Drug Toxicity	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.		[ 82]
Genetic Polymorphism	rs17216198
Site of GPD	chr10:99804028 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9900/1959 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Toxic Liver Disease	Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.		[ 82]
Genetic Polymorphism	rs2804402
Site of GPD	chr10:99781826 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.6480/1282 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Cisplatin	N.A.	Toxic Liver Disease	Allele G is not associated with clearance of unbound cisplatin when treated with cisplatin in people with Neoplasms as compared to allele A.		[ 23]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Kidney Tubular Necrosis, Acute	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 17]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclosporine	N.A.	Transplant Rejection	Genotype GG is not associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.		[ 13]
Mycophenolate Mofetil	N.A.	Transplant Rejection	Genotype GG is not associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.		[ 13]
Genetic Polymorphism	rs17216317
Site of GPD	chr10:99844350 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9880/1955 (Global)
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
N-desmethyltramadol	N.A.	Progression-free Survival	Genotype CT is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CC.		[ 50]
O-desmethyltramadol	N.A.	Progression-free Survival	Genotype CT is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CC.		[ 50]
Genetic Polymorphism	rs2804400
Site of GPD	chr10:99793502 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.6640/1314 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Kidney Disorder	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 40]
Genetic Polymorphism	rs3740067
Site of GPD	chr10:99844024 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G
Minor Allele Frequency	C=0.7280/1440 (Global)
Genotypes CG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Carbamazepine	N.A.	Leukopenia	Genotypes CG + GG is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype CC.		[ 69]
Genetic Polymorphism	rs7910642
Site of GPD	chr10:99781822 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	G=0.8610/1703 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lopinavir	N.A.	Leukopenia	Genotypes AA + AG is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype GG.		[ 122]
Genetic Polymorphism	rs2273897
Site of GPD	chr6:154962860 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.4770/943 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Emtricitabine	N.A.	Kidney Tubular Necrosis, Acute	Genotype TT is associated with increased concentrations of emtricitabine in people with HIV Infections and Pregnancy as compared to genotypes CC + CT.		[ 123]
Genetic Polymorphism	rs765027508
Site of GPD	chr10:99804043 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Toxic Liver Disease	Genotype AG is associated with increased exposure to methotrexate in men with Lymphoma, B-Cell.		[ 124]
Genetic Polymorphism	rs3740063
Site of GPD	chr10:99850966 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.6360/1258 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Transplant Rejection	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 36]
Genetic Polymorphism	rs3740074
Site of GPD	chr10:99811771 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.3630/718 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Transplant Rejection	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 36]
Genetic Polymorphism	rs2756109
Site of GPD	chr10:99798989 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C / G>T
Minor Allele Frequency	G=0.4950/979 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Transplant Rejection	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 36]
Genetic Polymorphism	rs4148398
Site of GPD	chr10:99832865 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.2670/528 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Transplant Rejection	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.		[ 36]
Genetic Polymorphism	rs2002042
Site of GPD	chr10:99828174 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.7200/1424 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Transplant Rejection	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 36]
Genetic Polymorphism	rs2804398
Site of GPD	chr10:99798877 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>T
Minor Allele Frequency	A=0.7030/1391 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele A.		[ 77]
Antiepileptics	N.A.	Peripheral Nervous System Diseases	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 40]
Genetic Polymorphism	rs4148396
Site of GPD	chr10:99832187 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.3150/623 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 77]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Genotypes CC + CT are associated with increased time to discontinuation or dose reduction when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.		[ 45]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Alopecia	Genotype CC is associated with increased likelihood of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.		[ 45]
Genetic Polymorphism	rs17222589
Site of GPD	chr10:99804266 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.9990/1977 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Peripheral Nervous System Diseases	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 40]
Genetic Polymorphism	rs3758395
Site of GPD	chr10:99842247 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.8810/1743 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Peripheral Nervous System Diseases	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.		[ 40]
Genetic Polymorphism	rs7080681
Site of GPD	chr10:99800412 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9840/1947 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tenofovir	N.A.	Nephrotoxicity	Allele A is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 4]
Genetic Polymorphism	rs12826
Site of GPD	chr10:99852563 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.7250/1434 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Vincristine	N.A.	Neurotoxicity Syndromes	Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 85]
References
1	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics. 2006 Nov;16(11):801-8.
2	The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan;23(1):29-33.
3	Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
4	Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006 Dec 1;194(11):1481-91.
5	Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009 Jun 1;48(11):e108-16.
6	NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005 Dec 13;112(24):3754-62.
7	Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J. 2013 Dec;13(6):507-13.
8	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007 Aug;17(8):647-56.
9	Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. Pharmacogenomics J. 2017 Jan;17(1):4-10.
10	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res. 2014 May 01;20(9):2466-75.
11	Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan;45(1):4-11.
12	Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012 Apr 01;118(7):1856-67.
13	Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008 Sep;21(9):879-91.
14	Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions. Eur J Clin Pharmacol. 2017 Sep;73(9):1129-1140.
15	A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genomics. 2015 Feb;25(2):82-92.
16	A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection. PLoS One. 2016 Jan 25;11(1):e0147724.
17	Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
18	Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics. 2012 Jan;13(2):185-90.
19	Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. Drug Metab Pharmacokinet. 2013;28(3):196-202.
20	Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. Biomed Pharmacother. 2021 Jan;133:111087.
21	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010 Dec;11(12):1703-13.
22	Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012 Jan;13(2):159-69.
23	Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy. Clin Pharmacol Ther. 2012 Jun;91(6):1022-6.
24	Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study. J Clin Pharm Ther. 2021 Dec;46(6):1557-1563.
25	Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome Med. 2016 Nov 08;8(1):119.
26	Impact of ABCC2 1249G>A and -24C>T Polymorphisms on Lacosamide Efficacy and Plasma Concentrations in Uygur Pediatric Patients With Epilepsy in China. Ther Drug Monit. 2023 Feb 01;45(1):117-125.
27	Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget. 2017 Feb 07;8(6):9388-9398.
28	Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
29	SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Pharmacogenomics. 2015;16(4):347-60.
30	Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy. Coll Antropol. 2013 Mar;37(1):41-5.
31	Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021 Apr 01;19(1):51.
32	Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics. 2011 Oct;21(10):624-30.
33	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018 Feb;19(3):175-184.
34	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chin J Cancer. 2016 Sep 2;35(1):85.
35	Effects of ABCB1, ABCC2, UGT2B7 and HNF4 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure. 2017 Oct;51:102-106.
36	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018 Dec;58(12):1541-1549.
37	Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res. 2016 Nov;127:186-190.
38	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. Pharmacogenomics J. 2020 Apr;20(2):202-212.
39	Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics. 2008 Apr;18(4):357-65.
40	Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 2011 Mar;12(3):319-25.
41	Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. Eur J Clin Pharmacol. 2014 Oct;70(10):1211-9.
42	ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci Ther. 2012 Aug;18(8):647-51.
43	ABCC2 as a novel covariate influencing oxcarbazepine pharmacokinetics in pediatric epilepsy: Insights from population modeling. Drug Metab Dispos. 2025 Jun;53(6):100090.
44	Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10;28(8):1287-93.
45	Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):572-9.
46	Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline. Pharmaceutics. 2022 Sep 21;14(10).
47	Association of ABCC2 polymorphism with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention. Front Pharmacol. 2022;13:889473.
48	Urinary coproporphyrin I/(I+III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. Br J Clin Pharmacol. 2014 Aug;78(2):329-42.
49	Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics. Front Pharmacol. 2024;15:1414059.
50	Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1. Forensic Sci Int Genet. 2025 Mar;76:103218.
51	Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J. 2015 Jun;15(3):263-71.
52	Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018 Jan 10;9(10):9114-9136.
53	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics J. 2019 Aug;19(4):390-400.
54	Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull. 2008 Nov;31(11):2137-42.
55	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. J Clin Pharmacol. 2018 Dec;58(12):1550-1556.
56	A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
57	Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Sci Rep. 2017 Apr 19;7:46537.
58	Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study. PLoS One. 2015 Nov 4;10(11):e0141931.
59	Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. Int J Mol Sci. 2015 Aug 25;16(9):20168-82.
60	Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 2014 Jul;15(10):1323-36.
61	Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica. 2008 Nov;38(11):1422-36.
62	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
63	Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Des Devel Ther. 2017;11:1135-1146.
64	Case report: Acute liver failure during deferasirox therapy and the potential role of pharmacogenetics. Front Pharmacol. 2024;15:1477755.
65	Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol. 2013 Feb;75(2):463-75.
66	Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy. J Pers Med. 2022 Apr 11;12(4).
67	Predictive Value of. Genet Test Mol Biomarkers. 2023 May;27(5):133-141.
68	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20.
69	A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine. Pharmacogenomics J. 2014 Oct;14(5):481-7.
70	The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis. J Clin Neurosci. 2017 Mar;37:6-14.
71	Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
72	Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024 Dec 12;16(12).
73	Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Antimicrob Agents Chemother. 2015;59(6):3240-5.
74	Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia. Blood Sci. 2023 Jan;5(1):32-38.
75	Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis. 2011 Jan 15;203(2):246-57.
76	Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. Haematologica. 2015 Feb;100(2):275-83.
77	Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. J Clin Pharmacol. 2020 Mar;60(3):361-368.
78	Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmgenomics Pers Med. 2013 Aug 26;6:93-8.
79	Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013 Feb;23(2):53-61.
80	Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients. Breast Cancer Res Treat. 2025 Jul;212(2):251-260.
81	Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One. 2014 Jan 3;9(1):e82681.
82	An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C. Pharmacogenomics J. 2019 Jun;19(3):240-248.
83	Impact of SLCO1B3 polymorphisms on clinical outcomes in lung allograft recipients receiving mycophenolic acid. Pharmacogenomics J. 2020 Feb;20(1):69-79.
84	Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenet Genomics. 2023 Jun 01;33(4):79-87.
85	Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016 May;17(7):731-41.
86	Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection. J Immunol Res. 2022;2022:3129389.
87	A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013 Oct;13(5):403-9.
88	Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients. Pharmacotherapy. 2017 May;37(5):535-545.
89	Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. Int J Hematol. 2013 Dec;98(6):702-7.
90	The Impact of ABCC2 -24C>T Gene Polymorphism on Graft Survival in Kidney Transplant Recipients. J Pers Med. 2024 Apr 22;14(4).
91	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother. 2014 Jan;69(1):241-5.
92	Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort. Pharmacogenet Genomics. 2015 Nov;25(11):541-7.
93	Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007 Jan;132(1):272-81.
94	CYP2C19 genotype and sodium channel blockers in lacosamide-treated children with epilepsy: two major determinants of trough lacosamide concentration or clinical response. Ther Adv Neurol Disord. 2024;17:17562864241273087.
95	Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. 2018 Aug;28(8):189-195.
96	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics J. 2019 Oct;19(5):473-479.
97	Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial. Pharmacogenet Genomics. 2018 Nov;28(11):245-250.
98	Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J. 2013 Jun;13(3):251-6.
99	Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. World J Gastroenterol. 2015 Feb 21;21(7):2116-23.
100	Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol. 2013 Apr;71(4):843-51.
101	Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs. 2013 Mar;24(3):310-4.
102	Influence of Calcineurin Inhibitors and Genetic Polymorphism of Transporters on Enterohepatic Circulation and Exposure of Mycophenolic Acid in Chinese Adult Renal Allograft Recipients. J Clin Pharmacol. 2023 Apr;63(4):410-420.
103	Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
104	Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis. Eur J Clin Pharmacol. 2016 Feb;72(2):247-8.
105	Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin. Basic Clin Pharmacol Toxicol. 2018 May;122(5):517-522.
106	ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. Onco Targets Ther. 2016 Apr 12;9:2121-9.
107	Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents. 2016 Feb;47(2):117-23.
108	Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL). Pediatr Hematol Oncol. 2020 Apr;37(3):185-197.
109	Association Between. Anticancer Res. 2024 Nov;44(11):5023-5033.
110	Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report. Pharmacogenomics. 2013 Sep;14(12):1389-96.
111	Impact ofUGT2B7and ABCC2genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients. Pharmacogenomics. 2018 Nov;19(17):1323-1334.
112	Genetic Polymorphisms of GGH and ABCC2 Are Associated with Methotrexate Intolerance in Patients with Rheumatoid Arthritis. J Clin Med. 2021 Sep 09;10(18).
113	Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin. Pharmacogenomics. 2018 Sep 01;19(14):1125-1132.
114	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics. 2018 Jul 01;19(11):913-925.
115	Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer. Cancer Chemother Pharmacol. 2024 Feb;93(2):121-127.
116	The Role of Candidate Polymorphisms in Drug Transporter Genes on High-Dose Methotrexate in the Consolidation Phase of the AIEOP-BFM ALL 2009 Protocol. Clin Transl Sci. 2025 Feb;18(2):e70136.
117	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics. 2009 Oct;10(10):1589-97.
118	Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011 Dec;21(12):884-93.
119	Genetic polymorphisms of ABCC2 and CBR3 can influence the efficacy andtoxicity of doxorubicin therapy in Egyptian patients with non-Hodgkin lymphoma. Xenobiotica. 2025 May 29:1-11.
120	MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy. Pharmacogenomics. 2017 Jul;18(10):981-985.
121	Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin-Johnson syndrome: a case report. Cancer Chemother Pharmacol. 2023 Oct;92(4):325-328.
122	Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans. Pharmacogenomics. 2016 May;17(7):679-90.
123	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. Pharmacogenomics. 2019 Mar;20(4):217-223.
124	A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics. 2005 May;15(5):277-85.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.